Summary: In a 12-month placebo-controlled trial in obese patients with type 2 diabetes and fatty liver, daily curcumin reduced liver fat, liver stiffness, and HbA1c and improved inflammatory and antioxidant markers, with only mild gastrointestinal side effects.
PICO Summary
| Element | Detail |
|---|---|
| Population | 227 obese adults with type 2 diabetes and liver steatosis (MASLD); 12-month, double-blind, placebo-controlled RCT, Thailand. |
| Intervention | Curcumin 1500 mg daily. |
| Comparison | Matching placebo. |
| Outcome | Curcumin significantly reduced liver fat content, liver stiffness, and HbA1c (all p<0.001). Inflammatory markers IL-1β and TNF-α fell, and antioxidant capacity (TAC, GPx, SOD) rose while malondialdehyde fell (all p<0.001). Liver and kidney function tests showed no clinically significant abnormalities; mild gastrointestinal discomfort was the most common adverse event. |
Curcumin for liver steatosis in type 2 diabetes
RCT · obese type 2 diabetes with MASLD · 12 months
Over 12 months, daily curcumin significantly lowered liver fat, liver stiffness, and HbA1c versus placebo in obese type 2 diabetes with fatty liver, with only mild gastrointestinal side effects. A reasonable low-risk adjunct to weight loss and glycaemic control.
Expert Commentary
This is one of the longer and more rigorous curcumin trials in a high-burden population, and its twelve-month duration is a genuine strength, since steatosis and its markers change slowly and short supplement studies often cannot detect meaningful effects. The findings are coherent and biologically grounded: reductions in liver fat and stiffness alongside lower inflammatory and oxidative markers fit curcumin’s proposed actions on lipogenesis, AMPK, NF-kappaB, and antioxidant pathways, and the concurrent HbA1c fall is a welcome bonus in a group with few approved liver-specific options. My reservations concern measurement and magnitude rather than direction. The formulation and the imaging modality for liver fat are not fully detailed, and bioavailability varies enormously between curcumin products, so results may not transfer to a standard turmeric capsule. The effect sizes, while significant, are modest next to weight loss, which remains the most effective intervention, and hard outcomes such as fibrosis progression were not assessed. Can I use this with my patients? Yes, as a low-risk adjunct. For a diabetic patient with fatty liver already pursuing weight loss and glycaemic control, a bioavailability-enhanced curcumin is a reasonable add-on, with a caution about antiplatelet and anticoagulant interactions, framed as complementary to proven measures rather than a substitute.
References
Yaikwawong M, Kamdee K, Chuengsamarn S. Curcumin attenuates liver steatosis via antioxidant and anti-inflammatory pathways in obese patients with type 2 diabetes mellitus: a randomized controlled trial. Int J Mol Sci. 2025;26(19):9286. doi:10.3390/ijms26199286